# US 2021/0060091 A1 · Bacteroides ovatus for Relieving Endotoxin Infection and Application thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0060091 A1
- Document ID: US20210060091A1
- Status: Published application
- Kind: A1
- Application number: 17/082,594
- Filed: 2020-10-28
- Published: 2021-03-04
- Earliest claimed: 2018-04-28
- Assignees: Jiangnan University
- Applicants: Jiangnan University
- Inventors: Wei CHEN; Qixiao ZHAI; Huizi TAN; Wenwei LU; Fengwei TIAN; Jianxin ZHAO; Hao ZHANG
- Web page: https://patentgrep.com/patent/US20210060091A1

## CPC

- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- C12N 1/20: Bacteria; Culture media therefor
- C12N 1/205: Bacterial isolates
- C12R 2001/01: Bacteria or Actinomycetales {; using bacteria or Actinomycetales}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

The disclosure discloses Bacteroides ovatus for relieving endotoxin infection and application thereof, and belongs to the technical field of microorganisms. The Bacteroides ovatus CCFM1021 of the disclosure has low immunogenicity, and can reduce the content of pro-inflammatory factors and increase the concentration of anti-inflammatory factors in the blood of mice infected with endotoxin, up-regulate the number of Foxp3+ regulatory T cells and stabilize the composition of the intestinal microbiota. A pharmaceutical composition of the Bacteroides ovatus CCFM1021 for relieving endotoxin infection has broad application prospects.

## Claims

### Claim 1

A composition comprising a bacterium of Bacteroides ovatus with a preservation number of GDMCC No: 60343, preserved at the Guangdong Microbial Culture Collection Center (GDMCC) on Mar. 29, 2018, with the preservation address of 5th Floor, Building 59, Courtyard 100, Xianlie Middle Road, Guangzhou, China.

### Claim 2 (depends on 1)

The composition of claim 1, further comprising a cytoprotective agent.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the cytoprotective agent comprises a phosphate buffer solution.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the composition comprising a cryopreserved agent, the cryopreserved agent is in a form of a powder prepared by a freeze-drying process or other processes, and comprises active Bacteroides ovatus with the content of 106 CFU/g or above.

### Claim 5 (depends on 2)

The composition of claim 2, further comprising pharmaceutically acceptable carriers.

### Claim 6 (depends on 5)

The composition of claim 5, wherein the amount of the bacterial agent in the pharmaceutical composition accounts for 15-35% by weight.

### Claim 7 (depends on 5)

The composition of claim 5, wherein the pharmaceutically acceptable carriers comprises one or more carriers selected from fillers, binders, wetting agents, disintegrants, lubricants and flavoring agents.

### Claim 8 (depends on 5)

The composition of claim 5, wherein the composition is in the form of granules, capsules, tablets, pills or oral liquid.

### Claim 9 (depends on 7)

The composition of claim 7, wherein the fillers are excipient diluents used for increasing the weight and volume of tablets to facilitate compressing, or excipient absorbents for absorbing excess liquid components in the raw materials.

### Claim 10 (depends on 7)

The composition of claim 7, wherein the binders are viscous substances that are added to a drug when the drug has no viscosity or insufficient viscosity, so as to facilitate granulation.

### Claim 11 (depends on 7)

The composition of claim 7, wherein the wetting agents are liquid that are added to a drug when the drug has no viscosity, so as to wet the raw materials and excipients of the drug to induce the viscosity and form granules.

### Claim 12 (depends on 7)

The composition of claim 7, wherein the disintegrants are excipients that are added to tablets to promote rapid disintegration into fine particles in gastrointestinal fluid.

### Claim 13 (depends on 7)

The composition of claim 7, wherein the lubricants are chemical substances that improve the mobility of tablets during processing and demoulding; and the flavoring agents are excipients used in drugs to improve or shield the undesirable smell and taste.

### Claim 14 (depends on 1)

A method of using the composition of claim 1, comprising relieving endotoxin infection, through ingesting the Bacteroides ovatus or the composition comprising the Bacteroides ovatus into a human intestinal tract.
